Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study Meeting Abstract


Authors: Beer, T. M.; Armstrong, A. J.; Sternberg, C. N.; Higano, C. S.; Rathkopf, D. E.; Loriot, Y.; Saad, F.; Joshua, A. M.; de Bono, J. S.; Venner, P. M.; Carles, J.; Mainwaring, P. N.; Evans, C. P.; Parli, T.; Mansbach, H. H.; Bhattacharya, S.; Van Os, S.; Phung, D.; Tombal, B. F.
Abstract Title: Enzalutamide (ENZA) in men with chemotherapy-Naive metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study
Meeting Title: 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901078
PROVIDER: wos
DOI: 10.1200/jco.2015.33.15_suppl.5036
Notes: Meeting Abstract: 5036 -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Dana Elizabeth Rathkopf
    245 Rathkopf